Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia.
Back to dashboard
Company Information
About this company
Key people
Kanya Rajangam
President, Head - Research and Development, Chief Medical Officer
Timothy Lu
Chief Executive Officer, Director
Jay Cross
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Bryan Baum
Director
Donald Tang
Director
James J. Collins
Independent Director
Feng Hsiung
Independent Director
Edward T. Mathers
Independent Director
Click to see more
Key facts
- Shares in issue31.15m
- EPICSNTI
- ISINUS8169441024
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$7.00m
- Employees39
- ExchangeNASDAQ
- Index
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.